Evaluation of the Safety of Deutetrabenazine at Higher Doses to Treat Chorea in Huntington’s Disease
Objective: To evaluate the safety and tolerability of deutetrabenazine >48 mg/d compared to ≤48 mg/d to treat Huntington’s disease (HD)–associated chorea in ARC-HD. Background: In…VMAT 2 inhibitor and Antipsychotic use in Individuals with Huntington’s Disease
Objective: To retrospectively investigate whether the concomitant use of VMAT2 inhibitors and antipsychotics in individuals with Huntington's disease (HD) is associated with an increased occurrence…Association between motor symptoms and striatal VMAT2 binding in PD: a PET study
Objective: In this study, we investigate the association between motor symptoms and striatal vesicular monoamine transporter type 2 (VMAT2) binding using 18F-FP-DTBZ PET in PD…Utility of VMAT2 inhibitors in management of stereotypy in children: a series of six patients
Objective: We aim to evaluate the effectiveness of VMAT2 inhibitors in the treatment of stereotypy. Background: Stereotypies are continual, rhythmic, patterned movements that can occur in typically-developing children, and are…Comparison of Safety and Tolerability of Deutetrabenazine (DTBZ) During Titration and Maintenance in Patients With Tardive Dyskinesia (TD)
Objective: To compare safety of DTBZ in titration vs maintenance using data from two 12-wk placebo (PBO)-controlled studies (ARM-TD and AIM-TD) and an open-label extension…Real-World Deutetrabenazine Dosing Patterns in Patients With Huntington’s Disease or Tardive Dyskinesia
Objective: To evaluate real-world treatment patterns and adherence to deutetrabenazine (DTBZ) in patients with Huntington’s disease (HD) or tardive dyskinesia (TD). Background: DTBZ is a…The Impact of Antipsychotic Dose Reduction Within a Medicare Population
Objective: To analyze the burden of antipsychotic (AP) dose reduction in Medicare patients with schizophrenia (SZ). Background: Tardive dyskinesia (TD) develops in patients treated with…Increased vesicular monoamine transporter alleviate MPTP-induced impairment of neurogenesis
Objective: In this study, we employed vesicular monoamine transporter 2–overexpressing mice (VMAT2-HI) to investigate the influence of increased vesicular storage of catacholamines on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced…PPMI driven sample size estimation for clinical trials in Parkinson’s disease
Objective: To utilize clinical, imaging and CSF data from the Parkinson’s Progression Markers Initiative (PPMI) to estimate the sample size for disease modification studies in…Comparing risperidone and olanzapine to tetrabenazine for the management of Huntington’s chorea
Objective: To compare the efficacy of risperidone and olanzapine to tetrabenazine (TBZ) for the management of Huntington’s chorea in Enroll-HD participants. Background: TBZ is provenly-effective…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- Next Page »